[1]裴 蕾,张滢滢.尤瑞克林治疗超出溶栓时间窗急性脑梗死的疗效[J].医学信息,2021,34(09):159-161.[doi:10.3969/j.issn.1006-1959.2021.09.043]
　PEI Lei,ZHANG Ying-ying.Efficacy of Urinary Kallidinogenase in the Treatment of Acute Cerebral Infarction Beyond the Thrombolytic Time Window[J].Medical Information,2021,34(09):159-161.[doi:10.3969/j.issn.1006-1959.2021.09.043]
点击复制

尤瑞克林治疗超出溶栓时间窗急性脑梗死的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年09期
页码:
159-161
栏目:
药物与临床
出版日期:
2021-05-01

文章信息/Info

Title:
Efficacy of Urinary Kallidinogenase in the Treatment of Acute Cerebral Infarction Beyond the Thrombolytic Time Window
文章编号:
1006-1959（2021）09-0159-03
作者:
裴 蕾; 张滢滢
（湖北江汉油田总医院神经内科1，中医科2，湖北 潜江 433124）
Author(s):
PEI Lei; ZHANG Ying-ying
(Department of Neurology1,Department of Traditional Chinese Medicine2,Hubei Jianghan Oilfield General Hospital, Qianjiang 433124,Hubei,China)
关键词:
急性脑梗死; 溶栓时间; Barthel指数
Keywords:
Acute cerebral infarction; Thrombolysis time; Barthel index
分类号:
R969.4
DOI:
10.3969/j.issn.1006-1959.2021.09.043
文献标志码:
A
摘要:
目的 研究尤瑞克林治疗超出溶栓时间窗急性脑梗死的临床疗效。方法 选取2019年3月~2020年3月我院诊治的64例超出溶栓时间窗急性脑梗死患者为研究对象，采用随机数字表法分为对照组和观察组，各32例。对照组采用常规治疗治疗，观察组在对照组基础上联合尤瑞克林治疗，比较两组临床治疗总有效率、侧肢循环开放情况、神经功能缺损评分、Barthel指数以及临床不良反应发生情况。结果 观察组治疗总有效率为93.75%，高于对照组的84.37%，差异有统计学意义（P＜0.05）；观察组眼前动脉、前交通、后交通、软脑膜侧支循环开放率均高于对照组，差异有统计学意义（P＜0.05）；观察组NIHSS评分低于对照组，BI评分高于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为6.25%，与对照组的9.37%比较，差异无统计学意义（P＞0.05）。结论 尤瑞克林治疗超出溶栓时间窗急性脑梗死临床疗效确切，可提升侧肢循环开放率，降低神经功能缺损，提高日常生活能力，且不增加不良反应发生几率。
Abstract:
Objective To study the clinical efficacy of Urinary Kallidinogenase in the treatment of acute cerebral infarction beyond the thrombolytic time window.Methods 64 patients with acute cerebral infarction beyond the thrombolysis time window who were diagnosed and treated in our hospital from March 2019 to March 2020 were selected as the research objects.Using random number table method, they were divided into control group and observation group, each with 32 cases.The control group was treated with conventional treatment, and the observation group was combined with Urinary Kallidinogenase on the basis of the control group. The total effective rate of clinical treatment, side limb circulation, neurological deficit score, Barthel index, and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.75%, which was higher than 84.37% in the control group,the difference was statistically significant (P＜0.05);The opening rates of anterior arteries, anterior traffic, posterior traffic, and pial collateral circulation in the observation group were higher than those in the control group,the difference was statistically significant (P<0.05);The NIHSS score of the observation group was lower than that of the control group, and the BI score of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05);The incidence of adverse reactions in the observation group was 6.25%, compared with 9.37% in the control group, the difference was not statistically significant (P>0.05).Conclusion Urinary Kallidinogenase has a definite clinical effect in the treatment of acute cerebral infarction beyond the thrombolytic time window. It can increase the open rate of lateral limb circulation, reduce neurological deficits, improve the ability of daily living, and does not increase the probability of adverse reactions.

参考文献/References:

[1]谷黎丽,田勇武,贺丹.不同TOAST分型急性脑梗死患者血清hs-CRP和LDL水平变化及临床意义[J].河北医科大学学报,2017,38(5):514-519,524. [2]曹志勇,丁妹,凌卓敏,等.尤瑞克林治疗超出溶栓时间窗急性脑梗死的临床疗效观察[J].中西医结合心脑血管病杂志,2017,15(2):239-241. [3]任军,姜亮,殷信道,等.探讨急性脑梗死不同治疗方法的TOAST分型及其影像学表现[J].磁共振成像,2017,8(8):561-566. [4]杜继慧.尤瑞克林治疗急性脑梗死临床疗效分析[J].中国卫生标准管理,2016,7(6):83-85. [5]朝浩,尹晓新,刘煜敏.尤瑞克林治疗急性脑梗死的临床疗效及对血清炎性因子水平、血液流变学的影响研究[J].实用心脑肺血管病杂志,2016,24(1):25-28. [6]李爱芹.尤瑞克林治疗急性脑梗死临床疗效观察[J].河北医学,2014,20(12):2090-2092. [7]杜翔,薛常虎.尤瑞克林在不同TOAST分型急性脑梗死临床治疗中应用观察[J].陕西医学杂志,2013,42(7):869-870. [8]郭玉兰.尤瑞克林在不同亚型急性脑梗死中的治疗效果观察[J].贵州医药,2016,40(6):598-600． [9]Winship IR.Cerebral collaterals and collateral therapeutics for acute ischemic stroke[J].Microcirculation,2015,22(3):228-236. [10]李秀芹,高勇.阿托伐他汀联合尤瑞克林对急性脑梗死患者临床疗效及内皮素水平的影响[J].中国老年学杂志,2016,36(9):2146-2148． [11]殷琪,许晋川,文国强,等.阿司匹林联合尤瑞克林治疗不同类型脑梗死患者疗效观察[J].华南国防医学杂志,2014,28(9):927-928． [12]Beyer SE,Thierfelder KM,von Baumgarten L,et al.Strategies of collateral blood flow assessment in ischemic stroke:prediction of the follow up infarct volume in conventional and dynamic CTA[J].American Journal of Neuroradiology,2015,36(3):488-494． [13]曹志勇,丁妹,凌卓敏,等.尤瑞克林治疗超出溶栓时间窗急性脑梗死的临床疗效观察[J].中西医结合心脑血管病杂志,2017,15(2):239-241． [14]Li C,ZhaO GF,He QY,et al.Study on the clinical efficacy of Human Urinary Kalllikrein in the treatment of acute cerebral infarction according to TOAST classification[J].Pak J Pharm Sci,2015,28(4 Suppl):1505-1510. [15]黄清华.尤瑞克林治疗超出溶栓时间窗急性脑梗死的临床效果探讨[J].基层医学论坛,2019,23(26):3752-3753.

相似文献/References:

[1]冯 湧.新一代抗凝血药阿加曲班的临床应用进展[J].医学信息,2018,31(02):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
　FENG Yong.Progress in Clinical Application of the New Generation Anticoagulant Agatripine[J].Medical Information,2018,31(09):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
[2]王 伟,宫秀群,余 亮.阿替普酶治疗急性脑梗死患者临床转归的影响因素[J].医学信息,2022,35(11):84.[doi:10.3969/j.issn.1006-1959.2022.11.022]
　WANG Wei,GONG Xiu-qun,YU Liang.The Influencing Factors of Clinical Outcome in Patients with Acute Cerebral Infarction Treated with Alteplase[J].Medical Information,2022,35(09):84.[doi:10.3969/j.issn.1006-1959.2022.11.022]
[3]陈建新.阿加曲班注射液治疗急性脑梗死的疗效及对血清VEGF、GLUT-1水平的影响[J].医学信息,2018,31(19):5.[doi:10.3969/j.issn.1006-1959.2018.19.002]
　CHEN Jian-xin.Effect of Argatroban Injection on Acute Cerebral Infarction and Its Effect on Serum VEGF and GLUT-1 Levels[J].Medical Information,2018,31(09):5.[doi:10.3969/j.issn.1006-1959.2018.19.002]
[4]刘 然.头颅MRI-DWI病灶数量及部位对脑梗死复发预测意义[J].医学信息,2018,31(22):172.[doi:10.3969/j.issn.1006-1959.2018.22.052]
　LIU Ran.The Significance of the Number and Location of MRI-DWI Lesions in Predicting the Recurrence of Cerebral Infarction[J].Medical Information,2018,31(09):172.[doi:10.3969/j.issn.1006-1959.2018.22.052]
[5]褚春沐.阿加曲班联合阿替普酶静脉溶栓治疗急性脑梗死的效果及对脑血管储备功能的影响[J].医学信息,2022,35(13):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
　CHU Chun-mu.Effect of Argatroban Combined with Alteplase Intravenous Thrombolysis on Acute Cerebral Infarction and its Effect on Cerebrovascular Reserve Function[J].Medical Information,2022,35(09):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
[6]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Medical Information,2019,32(09):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[7]王丹丹,王学建.动脉自旋标记在急性脑梗死中的应用[J].医学信息,2019,32(12):102.[doi:10.3969/j.issn.1006-1959.2019.12.031]
　WANG Dan-dan,WANG Xue-jian.Application of Arterial Spin Labeling in Acute Cerebral Infarction[J].Medical Information,2019,32(09):102.[doi:10.3969/j.issn.1006-1959.2019.12.031]
[8]赵宏伟.急性脑梗死的危险因素及临床诊治研究[J].医学信息,2019,32(18):44.[doi:10.3969/j.issn.1006-1959.2019.17.015]
　ZHAO Hong-wei.Risk Factors and Clinical Diagnosis and Treatment of Acute Cerebral Infarction[J].Medical Information,2019,32(09):44.[doi:10.3969/j.issn.1006-1959.2019.17.015]
[9]陶 林,马 婷.丁苯酞注射液、胶囊序贯疗法辅治急性进展性脑梗死的 疗效及其对神经功能的影响[J].医学信息,2019,32(18):135.[doi:10.3969/j.issn.1006-1959.2019.18.045]
　TAO Lin,MA Ting.Efficacy of Butylphthalide Injection and Capsule Sequential Therapy in the Treatment of Acute Progressive Cerebral Infarction and Its Effect on Neurological Function[J].Medical Information,2019,32(09):135.[doi:10.3969/j.issn.1006-1959.2019.18.045]
[10]朱丽娜,王宗立,顾萌萌.UA、Hcy和FIB与颈动脉粥样硬化斑块及 脑梗死关系的分析[J].医学信息,2019,32(18):173.[doi:10.3969/j.issn.1006-1959.2019.18.061]
　ZHU Li-na,WANG Zong-li,GU Meng-meng.Analysis of the Relationship Among UA, Hcy，FIB and Carotid Atherosclerotic Plaque， Cerebral Infarction[J].Medical Information,2019,32(09):173.[doi:10.3969/j.issn.1006-1959.2019.18.061]

更新日期/Last Update: 1900-01-01